Bayer Santé Familiale SAS, a prominent player in the healthcare industry, is headquartered in France and operates extensively across Europe. Founded in the early 20th century, the company has established itself as a leader in consumer health, focusing on over-the-counter medications, dietary supplements, and personal care products. Bayer Santé Familiale is renowned for its commitment to innovation, offering unique formulations that cater to diverse health needs. With a strong emphasis on quality and safety, the company has achieved significant milestones, including numerous product launches that have set industry standards. As a subsidiary of Bayer AG, Bayer Santé Familiale holds a notable market position, recognised for its trusted brands and dedication to improving family health. Its ongoing efforts in research and development continue to solidify its reputation as a key contributor to the consumer health sector.
How does Bayer Sante Familiale SAS's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Bayer Sante Familiale SAS's score of 35 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Bayer Sante Familiale SAS, headquartered in France, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Delpharm SAS, which may influence its climate commitments and emissions performance. As of now, Bayer Sante Familiale SAS has not publicly disclosed any reduction targets or significant climate initiatives. The absence of specific emissions data and reduction commitments suggests that the company may still be in the early stages of developing its climate strategy. Given its relationship with Delpharm SAS, any potential climate commitments or emissions data may be inherited from this parent organization. However, no specific figures or targets have been provided from Delpharm SAS that could be attributed to Bayer Sante Familiale SAS. In summary, Bayer Sante Familiale SAS is currently lacking detailed emissions data and defined climate commitments, reflecting a broader context within the industry where many companies are still formulating their sustainability strategies.
Access structured emissions data, company-specific emission factors, and source documents
| 2023 | 2024 | |
|---|---|---|
| Scope 1 | 39,887,000 | 00,000,000 |
| Scope 2 | 16,182,000 | 00,000,000 |
| Scope 3 | 695,597,000 | 000,000,000 |
Bayer Sante Familiale SAS's Scope 3 emissions, which decreased by 2% last year and decreased by approximately 2% since 2023, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 88% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Bayer Sante Familiale SAS has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.